HOME   |    PDF   |   


Title

Visual outcomes following intravitreal anti-VEGF therapy in diabetic retinopathy

 

Authors

Adesh Rundla1, Rituraj Sharma2 & Garvesh Modi1,*

 

Affiliation

1Department of Ophthalmology, Bundelkhand Medical College, Sagar, Madhya Pradesh, India; 2Department of Ophthalmology, V.K.S. Government Medical College, Neemuch, Madhya Pradesh, India; *Corresponding author

 

Email

Adesh Rundla - E-mail: adeshrundla@gmail.com
Rituraj Sharma - E-mail: riturajsharma1992@gmail.com
Garvesh Modi - E-mail: garveshmodi@gmail.com
 

Article Type

Research Article

 

Date

Received October 1, 2026; Revised October 31, 2026; Accepted October 31, 2026, Published October 31, 2026

 

Abstract

Diabetic retinopathy is a leading cause of preventable blindness and optimizing visual outcomes with intravitreal anti-vascular endothelial growth factor therapy remains a major clinical priority. Therefore, it is of interest to evaluate the effectiveness of intravitreal anti-vascular endothelial growth factor therapy in 100 patients with diabetic retinopathy using best corrected visual acuity, optical coherence tomography and fundus examination during follow-up. Treatment resulted in significant improvement in best corrected visual acuity and a significant reduction in central macular thickness, with superior outcomes observed in patients receiving early intervention and maintaining good glycemic control. Intravitreal anti-vascular endothelial growth factor therapy proved to be an effective and safe approach for improving both functional vision and retinal morphology in diabetic retinopathy. Thus, data shows the early use of intravitreal anti-vascular endothelial growth factor therapy to preserve vision and optimize long-term outcomes in patients with diabetic retinopathy.

 

Keywords

Diabetic retinopathy (DR), anti-VEGF, intravitreal injection, visual acuity, diabetic macular edema (DME), retina

 

Citation

Rundla et al. Bioinformation 22(10): 6326-6330 (2026)

 

Edited by

Vini Mehta

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.